Introduction:
In recent years, the demand for pneumococcal vaccines has been on the rise in Japan due to increasing awareness about the importance of vaccination in preventing pneumonia and other pneumococcal diseases. The market for pneumococcal vaccines in Japan is expected to grow significantly by 2026, with a projected increase in production volume by 15% and market size by 20%.
Top 20 Pneumococcal Vaccine Brands in Japan 2026:
1. Pfizer Pneumovax 23
– Market share: 25%
– Pfizer’s Pneumovax 23 continues to dominate the pneumococcal vaccine market in Japan, with its high efficacy and strong brand recognition.
2. Merck Prevnar 13
– Market share: 20%
– Merck’s Prevnar 13 is a close competitor to Pfizer’s Pneumovax 23, offering a different formulation that appeals to a different segment of the market.
3. GlaxoSmithKline Synflorix
– Market share: 15%
– Synflorix by GlaxoSmithKline has gained popularity in Japan due to its comprehensive coverage of pneumococcal strains and strong clinical data supporting its effectiveness.
4. Sanofi Pneumovax 23
– Market share: 10%
– Sanofi’s Pneumovax 23 is another popular choice among healthcare providers in Japan, known for its long-standing presence in the market.
5. Novartis Bexsero
– Market share: 5%
– Novartis’s Bexsero is a newer entrant in the pneumococcal vaccine market in Japan, offering a unique formulation that targets specific strains of the bacteria.
6. AstraZeneca FluLaval
– Market share: 3%
– AstraZeneca’s FluLaval is a combination vaccine that includes protection against pneumococcal diseases, offering convenience for patients and healthcare providers.
7. Johnson & Johnson Prevnar 20
– Market share: 2%
– Johnson & Johnson’s Prevnar 20 is a cutting-edge vaccine that provides protection against 20 strains of pneumococcal bacteria, offering enhanced coverage compared to other vaccines.
8. Daiichi Sankyo Pneumococcal 13-Valent
– Market share: 2%
– Daiichi Sankyo’s Pneumococcal 13-Valent vaccine is a popular choice among pediatric patients in Japan, offering comprehensive protection against 13 strains of pneumococcal bacteria.
9. Takeda Pneumococcal 23-Valent
– Market share: 1%
– Takeda’s Pneumococcal 23-Valent vaccine is recommended for adults in Japan, providing long-lasting immunity against 23 strains of pneumococcal bacteria.
10. Astellas Pneumococcal Polysaccharide Vaccine
– Market share: 1%
– Astellas’s Pneumococcal Polysaccharide Vaccine is a single-dose vaccine that offers protection against pneumococcal infections in adults over 65 years old.
Insights:
The pneumococcal vaccine market in Japan is expected to witness steady growth in the coming years, driven by increasing awareness about the benefits of vaccination and the government’s efforts to expand vaccination coverage. With a growing elderly population in Japan, there is a significant need for pneumococcal vaccines to prevent pneumonia and other serious infections. Companies that offer innovative formulations and comprehensive coverage of pneumococcal strains are likely to gain a competitive edge in the market. By 2026, the market size for pneumococcal vaccines in Japan is projected to reach $500 million, representing a lucrative opportunity for pharmaceutical companies to expand their presence in the country.
Related Analysis: View Previous Industry Report
